Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
Changes in cellular proteins associated with the expression of human immunodeficiency virus type 1 trans-activator protein Tat.
DNA Cell Biol. 1993 Nov;12(9):831-7. Unique Identifier : AIDSLINE MED/94030618 Ranganathan PN; Ranganathan S; Srinivasan A; Department of Biochemistry, Thomas Jefferson University,; Philadelphia, PA 19107.
Abstract:
Earlier studies have revealed a distinct class of regulatory proteins known as trans-activator proteins in diverse biological systems. These proteins have been shown to act on both homologous and heterologous promoter targets. Activation of heterologous targets is speculated to be an integral part of virus-induced pathogenesis. To verify this hypothesis, stable Tat-producing human rhabdomyosarcoma (RD) cell lines were generated. These cell lines produced significant levels of functional Tat, as measured by transfection with the reporter plasmid pLTR-CAT. Tat-producing cells, although morphologically similar to the control, exhibited a slower growth rate. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the cellular proteins from control (tat-) and tat+ cells revealed increased quantities of 34- and 40-kD proteins along with the appearance of a new 74-kD protein in tat+ cells. Subsequent two-dimensional gel analysis revealed several additional differences. Tat+ cell lines produced two proteins of M(r) 19.5 and 44 kD anew, while proteins with M(r) 14.5, 42, and 52.5 kD were in greater abundance. Interestingly, a 26-kD protein that was originally present in the G418+/tat- (control) sample disappeared in the presence of Tat. These data support a possible modulator role for Tat in cellular gene expression.
Keywords: Cell Line Electrophoresis, Gel, Two-Dimensional Gene Expression Regulation, Viral Gene Products, tat/*METABOLISM Human Proteins/GENETICS/*METABOLISM Support, U.S. Gov't, P.H.S. Transfection JOURNAL ARTICLE 940228
M9420781
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.